Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Patricia M. Sassoli"'
Publikováno v:
Angiogenesis. 9:171-176
The alphavbeta3 integrin plays an important role in tumor growth and angiogenesis. Inhibition of this receptor by intact bivalent antibodies has been shown to inhibit angiogenesis and tumor growth. In this study we tested the chimeric Fab of 7E3 (c7E
Autor:
Robert Jordan, Patricia M. Sassoli, Tam Susan H, Dean J. Kereiakes, Mark A. Nedelman, Marian T. Nakada
Publikováno v:
Journal of Thrombosis and Thrombolysis. 14:15-24
Background: Tirofiban and eptifibatide are currently approved for the medical stabilization of non-ST segment elevation acute coronary syndromes. In patients undergoing percutaneous coronary intervention (PCI) during infusion of these drugs, conversi
Autor:
Zhao Zhou, Mohit Trikha, Robert Jordan, Marian T. Nakada, Patricia M. Sassoli, Eva Emmell, Tam Susan H
Publikováno v:
Thrombosis and Haemostasis. 85:896-902
SummaryAbciximab (c7E3 Fab, ReoPro®) blocks GPIIb/IIIa and αvβ3 and inhibits thrombotic and proliferative events only in humans and non-human primates. The bivalent F(ab’)2 fragment is an effective anti-thrombotic agent in canine models. In the
Publikováno v:
Circulation. 98:1085-1091
Background —Large, randomized, and blinded clinical trials (EPIC, EPILOG, and CAPTURE) have demonstrated that abciximab (ReoPro, chimeric 7E3 Fab) markedly reduces thrombotic events associated with percutaneous transluminal coronary interventions.
Autor:
Marian T, Nakada, Patricia M, Sassoli, Susan H, Tam, Mark A, Nedelman, Robert E, Jordan, Dean J, Kereiakes
Publikováno v:
Journal of thrombosis and thrombolysis. 14(1)
Tirofiban and eptifibatide are currently approved for the medical stabilization of non-ST segment elevation acute coronary syndromes. In patients undergoing percutaneous coronary intervention (PCI) during infusion of these drugs, conversion to abcixi